(1/5) Encouraging pre-print out of Korea (though some important limitations to note): a collection of already FDA-approved drugs show strong efficacy against #Covid_19 in cell cultures. They highlighted two they found particularly promising: #niclosamide and #ciclesonide.
(2/5) ciclesonide PROS: 1. already been used on patients in Japan www3.nhk.or.jp/nhkworld/en/ne… 2. Appears specific to coronoavirus biorxiv.org/content/10.110… 3. Can be administered by inhalation
(3/5) #ciclesonide CONS: #MERS-CoV treated with ciclesonide developed resistance, upping the likelihood of resistance emerging in #SARSCoV2 SARS. I find this concerning because "pushing" the virus to evolve could drive its evolution down paths of greater mortality or infectivity
(4/5) niclosamide PROS: 1. effective against other coronoviruses "antiviral properties against SARS- and MERS-CoV" 2. "very potent antiviral activity against SARS-CoV-2 (IC50 = 0.28 μ M)"
(5/5) niclosamide CONS: 1. "niclosamide suffers a pharmacokinetic flaw of low adsorption"
